A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia
Phase of Trial: Phase III
Latest Information Update: 19 Mar 2019
Price : $35 *
At a glance
- Drugs Desmopressin (Primary)
- Indications Nocturia
- Focus Registrational; Therapeutic Use
- Sponsors Allergan; Serenity Pharmaceuticals Corporation
- 15 Oct 2018 Results presented at the American Urogynecologic Society Annual Scientific Meeting, Pelvic Floor Disorder (PFD) Week 2018.
- 15 Oct 2018 Results presented in an Avadel Pharmaceuticals Media Release.
- 05 Oct 2017 Results from pooled post-hoc analysis of this and another phase III trial presented in an Avadel Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History